Faculty Publications in Leukemias

Long-Term Outcomes after Treatment with Clofarabine?±?Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS.
Biol Blood Marrow Transplant. 2016 Oct;22(10):1792-800.

Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, Cooper B, Dubberke ER, Engemann AM, Freifeld AG, Greene JN, Ito JI, Kaul DR, Lustberg ME, Montoya JG, Rolston K, Satyanarayana G, Segal B, Seo SK, Shoham S, Taplitz R, Topal J, et al.
J Natl Compr Canc Netw. 2016 Jul;14(7):882-913.

The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia.
Brunstein C, Zhang MJ, Barker J, St Martin A, Bashey A, de Lima M, Dehn J, Hematti P, Perales MA, Rocha V, Territo M, Weisdorf D, Eapen M.
Haematologica. 2017 May;102(5):941-947.

A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, Hamadani M, Tse WW, Lazarus HM.
Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):428-432.e2.

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.
Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, et al.
Cancer. 2016 Oct;122(19):3005-3014.

Midostaurin: an emerging treatment for acute myeloid leukemia patients.
Gallogly MM, Lazarus HM.
J Blood Med. 2016 Apr 19;7:73-837

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.
Kanakry CG, Bolaños-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, Mielcarek M, Medeot M, Gojo I, Smith BD, Kanakry JA, Borrello IM, Brodsky RA, Gladstone DE, Huff CA, Matsui WH, Swinnen LJ, Cooke KR, Ambinder RF, Fuchs EJ, de Lima MJ, Andersson BS, et al.
Blood. 2017 Mar 9;129(10):1389-1393.

Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.
Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B.
Biol Blood Marrow Transplant. 2017 Aug;23(8):1359-1366.

Intra-osseous Co-transplantation of CD34-selected Umbilical Cord Blood and Mesenchymal Stromal Cells.
Metheny L 3rd, Eid S, Lingas K, Reese J, Meyerson H, Tong A, de Lima M, Huang AY.
Hematol Med Oncol. 2016;1(1):25-29.

Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, Beitinjaneh A, Chen YB, DeFilipp Z, Gale RP, Kebriaei P, Kharfan-Dabaja M, Lazarus HM, Nishihori T, Olsson RF, Oran B, Rashidi A, Rizzieri DA, Tallman MS, de Lima M, Khoury HJ, Sandmaier BM, et al.
Cancer. 2017 Jun 1;123(11):2035-2042.

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, et al.
J Natl Compr Canc Netw. 2017 Jul;15(7):926-957.

Understanding population-wide haplotype frequencies of human leukocyte antigen (HLA) alleles in linkage disequilibrium is important for hematopoietic stem cell transplantation.
Otegbeye F.
Rev Bras Hematol Hemoter. 2017 Jul - Sep;39(3):187-188.

Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia.
Rosko A, Wang HL, de Lima M, Sandmaier B, Khoury HJ, Artz A, Brammer J, Bredeson C, Farag S, Kharfan-Dabaja M, Lazarus HM, Marks DI, Bufarull RM, McGuirk J, Mohty M, Nishihori T, Nivison-Smith I, Rashidi A, Ringden O, Seftel M, Weisdorf D, Bachanova V, et al.
Am J Hematol. 2017 Jan;92(1):42-49.

Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.
Segal E, Martens M, Wang HL, Brazauskas R, Weisdorf D, Sandmaier BM, Khoury HJ, de Lima M, Saber W.
Cancer. 2017 Sep 1;123(17):3346-3355

Co-occurrence of type I CALR and two MPL mutations in patient with primary myelofibrosis.
Tashkandi H, Moore EM, Tomlinson B, Goebel T, Sadri N.
Ann Hematol. 2017 Aug;96(8):1417-1418.

Isolated skin relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.
Ueda M, Silva C, Baer L, Caimi PF, Cooper K, Honda K, de Lima M.
Rev Bras Hematol Hemoter. 2017 Jan - Mar;39(1):77-79.

Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.
Weisdorf DJ, Millard HR, Horowitz MM, Hyare PS, Champlin R, Ho V, Mielcarek M, Rezvani A, Stockerl-Goldstein K, Khoury HJ, De Lima M, Saber W, Sandmaier B, Zhang MJ, Eapen M.
Cancer. 2017 Jun 1;123(11):2025-2034.